MiniMed Group (NASDAQ:MMED) Reaches New 12-Month Low – Should You Sell?

Posted by Trevor Kearing on May 14th, 2026

MiniMed Group Inc (NASDAQ:MMED – Get Free Report) reached a new 52-week low during mid-day trading on Tuesday . The company traded as low as $11.10 and last traded at $11.16, with a volume of 578097 shares changing hands. The stock had previously closed at $11.57.

Wall Street Analyst Weigh In

Several brokerages have recently commented on MMED. Morgan Stanley started coverage on shares of MiniMed Group in a report on Tuesday, March 31st. They set an “overweight” rating and a $19.00 target price on the stock. Bank of America started coverage on MiniMed Group in a research report on Tuesday, March 31st. They set a “buy” rating and a $27.00 price target on the stock. Wall Street Zen upgraded MiniMed Group to a “hold” rating in a research note on Saturday, March 14th. Deutsche Bank Aktiengesellschaft started coverage on MiniMed Group in a research report on Tuesday, March 31st. They set a “buy” rating and a $20.00 target price for the company. Finally, The Goldman Sachs Group began coverage on MiniMed Group in a report on Tuesday, March 31st. They set a “buy” rating and a $24.00 target price on the stock. One investment analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and two have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $22.25.

Read Our Latest Report on MMED

MiniMed Group Trading Up 0.4%

The company has a fifty day moving average of $14.35.

MiniMed Group Company Profile

(Get Free Report)

We are a scaled global medical technology company that develops, manufactures, and markets a comprehensive suite of solutions for the management of diabetes. Since our founding more than 40 years ago, we have pioneered groundbreaking innovation and served the needs of our customers across the globe in service of our mission to make every day a better day for people with diabetes. Today, we are the only player in the market that commercializes all parts of an integrated diabetes management system.